Resources / Inter-laboratory variability of HER2 low analysis using artificial intelligence
Qualitopix®
Inter-laboratory variability of HER2 low analysis using artificial intelligence
Originally presented at ECP 2023
Background

Pathologists look for HER2 immunohistochemical expression in breast carcinoma representing HER2 amplification. The used tests are validated for HER2-high, e.g. score 2+ or 3+. Treatment of HER2-low breast carcinoma is emerging for HER2 expressing tumors with a score of 1+ or 2+ without amplification. In this study, immunohistochemical detection of HER2-low is tested for inter- and intralaboratory reproducibility in The Netherlands. Can the HER2-high test be used to detect eligibility for HER2-low treatment as well?

Authors and institutions

Nils ‘t Hart1, Maran Eenkhoorn1, Henrik Høeg2 and David Dabbs3

  1. Isala, Zwolle, The Netherlands
  2. Visiopharm, Hørsholm, Denmark
  3. University of Pittsburgh Medical Center, United States
Questions? We’re here to help.
Contact us
Success
Your message has been successfully sent!